Results 91 to 100 of about 42,899 (196)

Oxidative and Antioxidant Systems in Ferroptosis of Cancer: Mechanisms, Regulations, and Therapeutic Targeting

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Ferroptosis is governed by the balance between reactive oxygen species (ROS)‐driven lipid peroxidation and a multi‐tiered antioxidant network. ROS sources include mitochondrial electron transport chain, voltage‐dependent anion channels, NADPH oxidases, and endoplasmic reticulum‐resident oxidoreductases, while antioxidant defenses span the primary GSH ...
Deepak K, Pritam Kumar Roy, Maniklal Shee, Budhaditya Mukherjee, Aoife Ward Gahlawat, Mahitosh Mandal   +5 more
wiley   +1 more source

Identification of Predictive Factors for Isolated Brain Progression in Patients With Cerebral Metastatic Melanoma After Treatment With Stereotactic Brain Radiotherapy

JEADV Clinical Practice
Background Melanomas often metastasize to the brain, leading to a significantly poor prognosis despite advances in local and systemic treatments. In clinical practice, we frequently observe varying response patterns and progression dynamics between ...
Manuel Croix, Justine Lequesne, Julien Geffrelot, Anne Dompmartin, Jean Matthieu L'orphelin   +4 more
doaj   +1 more source

Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer

The Prostate, Volume 86, Issue 13, Page 1341-1351, September 15, 2026.
ABSTRACT Background For patients with unfavorable intermediate or high risk localized prostate cancer receiving definitive radiotherapy, androgen deprivation therapy reduces recurrence and improves survival but is underutilized due to toxicity concerns. Patients who forgo initial ADT may later require salvage ADT.
Jiaye Shen, Aaron J. Katz, Yahui Xie, Ronald C. Chen, Mutlay Sayan   +4 more
wiley   +1 more source

Retrospective Analysis of Survival and Adverse Effects Associated With Stereotactic Body Radiation Therapy in 12 Dogs With Hepatocellular Carcinoma

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 485-498, September 2026.
ABSTRACT This retrospective analysis evaluated 12 dogs with hepatocellular carcinoma (HCC) who received stereotactic body radiation therapy (SBRT). Dogs received between 6 and 25 Grey (Gy) per fraction for 1–5 fractions for a total dose of 13–30 Gy. Eleven patients (92%) experienced acute adverse effects (AE), with the majority being VRTOG grade 2–3 ...
Victoria Lee Newberry, Mary‐Keara Boss, Del Leary, Tiffany W. Martin   +3 more
wiley   +1 more source

The Definitive‐Intent 10‐Fraction Radiotherapy Protocol (‘The Zurich Protocol’) Yields Lasting Tumour Control and Survival in Dogs With Intracranial Meningiomas

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 601-610, September 2026.
ABSTRACT Moderately hypofractionated definitive‐intent radiotherapy protocols can be used for canine intracranial meningiomas to shorten overall treatment time while maintaining tumour control and limiting normal tissue toxicity. This retrospective study evaluated oncologic outcomes, toxicity, and radiation dose‐volume‐related prognostic factors in ...
Carlotta Ahrens, Sergejs Unterkirhers, Carla Rohrer Bley   +2 more
wiley   +1 more source

Use of the IlluminOss Photodynamic Bone Stabilisation System Following Stereotactic Body Radiation Therapy for Limb‐Sparing in Six Dogs With Presumptive Appendicular Osteosarcoma

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 611-620, September 2026.
ABSTRACT Osteosarcoma is the most common primary bone tumour in dogs, with approximately 75% of cases occurring in the appendicular skeleton. Standard‐of‐care therapy consists of limb amputation followed by carboplatin chemotherapy. A minority of dogs have limb‐sparing treatments including stereotactic body radiation therapy (SBRT) or surgery. SBRT has
Emily A. Pope, Vincent A. Wavreille, Janis L. Lapsley, Eric M. Green, William C. Kisseberth, Robert Rabiner, Laura E. Selmic   +6 more
wiley   +1 more source

Disease‐free survival as a surrogate outcome for localized kidney cancer—A systematic review and meta‐analysis

Cancer, Volume 132, Issue 16, 15 August 2026.
Abstract Background Disease‐free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (RCC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting.
Constanza Martinez, David Chen, Russell Leong, Nicholas Lum, Karren Xiao, Laith Almasri, Christian K. Kollmannsberger, Srinivas Raman   +7 more
wiley   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, Volume 20, Issue 8, Page 2040-2053, August 2026.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Application of an updated severity‐based FMEA approach to Radiation Therapy QA: A multi‐institutional exercise

Journal of Applied Clinical Medical Physics, Volume 27, Issue 8, August 2026.
Abstract Background External beam radiation therapy (RT) involves many complex steps to safely and reliably treat patients. The radiation oncology community has adopted process maps and failure modes and effects analysis (FMEA) to analyze risk using the TG‑100 methodology, but the traditional TG‑100–endorsed risk priority number (RPN) has recognized ...
Alejandra Rangel, Ryan Studinski, Ady Abdellatif, Leigh Conroy, Jenna King, Humza Nusrat, Michael Oliver   +6 more
wiley   +1 more source

Evaluation of dosimetric impact and plan robustness of MLC motion and setup errors in SRS for multiple brain metastases

Journal of Applied Clinical Medical Physics, Volume 27, Issue 8, August 2026.
Abstract Background HyperArc is an effective technique for treating multiple small brain metastases using high‐definition, precise radiation. However, the small size of individual lesions makes treatment vulnerable to inherent inaccuracies from beam‐limiting devices such as multi‐leaf collimators (MLCs), as well as patient setup errors.
Huijun Xu, Hong Zhang, Weiguang Yao, Jinghao Zhou, Yannick Poirier, Junliang Xu, Stewart Becker, Guozhen Luo, Mark Mishra, Shifeng Chen, Baoshe Zhang   +10 more
wiley   +1 more source